
Pharmaceutical Executive
Building an effective drug forecasting model today requires a revamped approach.

Pharmaceutical Executive
Building an effective drug forecasting model today requires a revamped approach.

Pharmaceutical Executive
At first glance Obamacare developments for the American Rx industry in 2015 appear fairly benign. However, digging deeper suggests that each, in its own way, could cause various actions with potential for substantial uncertainty for the U.S. pharmaceutical industry next year. If your response to this profound observation was, “Really, what’s new?” - read on.

Pharmaceutical Executive
Pharm Exec profiles Express Scripts' Chief Medical Officer, Dr. Steve Miller, whose rise to prominence as an articulate critic of drug industry prices symbolizes the growing clout of America's largest pharmacy benefit manager.

Pharmaceutical Executive

Pharmaceutical Executive
US researchers and regulators continue to support the use of randomized clinical trials to test potential treatments and vaccines to combat the Ebola virus, despite objections that this approach is unethical and unfair to vulnerable populations

Pharmaceutical Executive
The Food and Drug Administration is moving fast to implement the drug compounding provisions of new Drug Quality and Security Act (DQSA), issuing new guidance to spur registration by outsourcing facilities just days after President Obama signed the new bill into law.

Pharmaceutical Executive
For Moe Alsumidaie, the most concrete definition for patient centricity is “a dynamic process through which the patient regulates the flow of information to and from him/her via multiple pathways to exercise choice that is consistent with his/her preferences, values and beliefs.

Pharmaceutical Executive
Not all companies are big, small companies are scared, and myths drive behavior, stated Kay Holcombe, Senior Vice President, Science Policy at Biotechnology Industry Organization (BIO).

Pharmaceutical Executive
Cleveland Clinic's Pick of Top 10 Advances for 2015.

Pharmaceutical Executive
The pharmaceutical and biotechnology industries, like all industries, are facing industry-specific changes coupled with disruptive events in the external global environment.

Pharmaceutical Executive
The innovation debate (Why isn’t there more or it? How much should we pay for it? Just what is it anyway?!) remains a lively one in the UK. Lord Saatchi’s Medical Innovation Bill is just one part of this debate.

Pharmaceutical Executive
The battle against hepatitis C (HCV) is a relatively new, and highly dynamic, one.

Pharmaceutical Executive
“Only those who risk going too far can possibly find out how far they can go,” said T.S. Elliot. Cancer Research UK (CRUK) followed this advice when it decided to have its Center for Drug Development (CDD) adopt a risk-based monitoring (RBM) approach across its entire portfolio of clinical trials.

Pharmaceutical Executive
I can’t help imagining the cocktail party of 2018 as a scene from one of those a low-budget sci-fi film aired late at night. Imagine: A living room packed with people too busy to chat with each other as they balance their drinks with one hand and monitor their sleeves of devices and smartphones with the other - emailing, texting checking their wearable ECGs (electrocardiograms); glucose monitors and even insulin pumps.

Pharmaceutical Executive
The past year has brought significant changes not only in regulatory mandates and guidances but also regarding a broader overall emphasis on coordination of information and processes.

Pharmaceutical Executive
Shire plans to relocate more than 500 positions to Massachusetts from its Chesterbrook, PA, site and establish Lexington, MA, as the company’s US operational headquarters.

Pharmaceutical Executive
The Tufts University Center for the Study of Drug Development (CSDD) released its latest research on the costs and timeframes required for launching a new drug.

Pharmaceutical Executive
Last week, the Access to Medicine Foundation released its 2014 Index rating the performance of companies in broadening access to medicines in low and middle-income countries.

Pharmaceutical Executive
The European Medicines Agency (EMA) has published its revised policy on handling declarations of interests for scientific-committee members and experts.

Pharmaceutical Executive
CytRx announced on Tuesday that FDA gave notice of a partial clinical hold for trials for its oncology candidate aldoxorubicin.

Pharmaceutical Executive
The Pharmaceutical Care Management Association (PCMA), an organization that represents the nation’s leading pharmacy benefit managers (PBMs), which administer prescription drug plans for over 210 million Americans, released a new white paper investigating FDA’s influence on drug prices and competition in the pharmaceutical marketplace.

Pharmaceutical Executive
A cool $2.6 billion is the going rate to develop and gain market approval for a drug, according to the recent study by the Tufts Center for the Study of Drug Development (CSDD).

Pharmaceutical Executive
The pharmaceutical market is beginning to show signs of stability, with a review of 30 leading companies highlighting combined revenues of $718.7 billion in 2013, down just 0.2% from 2012, according to GlobalData.

Pharmaceutical Executive
While flipping through my emails recently, I froze before an image that appeared on my screen. An old Rx colleague had sent me a graph, mapping out the 2014 U.S. sales achieved by Gilead’s Hep C drug, Sovaldi. It was stunning.

Pharmaceutical Executive
Peter O’Donnell’s recent Applied Clinical Trials blog, ‘Who’s in charge of Medicines in Brussels?‘, has been overtaken by history, with the departure of Guido Rasi from his post of Executive Director of the European Medicines Agency.

Pharmaceutical Executive
In response to a letter the European Medicines Agency received from the European Ombudsman on Oct. 27, 2014, the agency is clarifying its policy on commercially confidential information.

Pharmaceutical Executive
Johnson & Johnson completed the acquisition of Alios BioPharma, a privately held clinical-stage biopharmaceutical company focused on developing therapies for viral diseases, for a total purchase price of approximately $1.75 billion in cash.

Pharmaceutical Executive
Merck KGaA CEO Stefan Oschmann spoke last week in New York as he accepted the two-year role as president of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the R&D industry’s global trade group based in Geneva.

Pharmaceutical Executive
The past decade has seen considerable growth in the Indian pharmaceutical industry. The country has emerged as a key supplier of high quality and affordable medicines not only to the developing world, but also to developed economies.

Pharmaceutical Executive
The Brazilian economy is being impacted by internal and external factors, and forecast figures are being quickly revised downwards. Market research released by Brazil’s Central Bank revised average analysts’ projections for economic growth in 2014 down to 0.70% from 0.90% four weeks earlier(1).